Elo Mutual Pension Insurance Co Purchases New Holdings in Quest Diagnostics Incorporated $DGX

Elo Mutual Pension Insurance Co acquired a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) in the 3rd quarter, HoldingsChannel reports. The firm acquired 10,632 shares of the medical research company’s stock, valued at approximately $2,026,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. MTM Investment Management LLC purchased a new stake in shares of Quest Diagnostics during the second quarter worth approximately $29,000. True Wealth Design LLC raised its position in Quest Diagnostics by 369.7% during the 3rd quarter. True Wealth Design LLC now owns 155 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares during the last quarter. AlphaQuest LLC raised its position in Quest Diagnostics by 18,400.0% during the 2nd quarter. AlphaQuest LLC now owns 185 shares of the medical research company’s stock worth $33,000 after buying an additional 184 shares during the last quarter. First Horizon Corp acquired a new stake in shares of Quest Diagnostics in the 3rd quarter worth $33,000. Finally, Rexford Capital Inc. purchased a new stake in shares of Quest Diagnostics in the second quarter valued at about $36,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Quest Diagnostics Stock Performance

DGX opened at $208.23 on Thursday. Quest Diagnostics Incorporated has a 1-year low of $157.20 and a 1-year high of $213.50. The stock has a market cap of $22.88 billion, a P/E ratio of 23.80, a P/E/G ratio of 2.69 and a beta of 0.66. The stock’s 50 day simple moving average is $190.63 and its 200 day simple moving average is $185.47. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.04 and a quick ratio of 0.96.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Tuesday, February 10th. The medical research company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.35 by $0.07. The firm had revenue of $2.81 billion during the quarter, compared to analysts’ expectations of $2.75 billion. Quest Diagnostics had a return on equity of 15.57% and a net margin of 8.99%.Quest Diagnostics’s revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.23 earnings per share. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. As a group, equities analysts anticipate that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics declared that its board has authorized a share buyback program on Tuesday, February 10th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 4.7% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Quest Diagnostics Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 20th. Investors of record on Monday, April 6th will be paid a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Monday, April 6th. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.80. Quest Diagnostics’s dividend payout ratio is currently 36.57%.

Insider Buying and Selling at Quest Diagnostics

In other news, SVP Michael E. Prevoznik sold 1,111 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $204.83, for a total value of $227,566.13. Following the sale, the senior vice president directly owned 38,371 shares in the company, valued at $7,859,531.93. This represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Catherine T. Doherty sold 1,433 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $204.83, for a total value of $293,521.39. Following the transaction, the executive vice president owned 68,402 shares of the company’s stock, valued at $14,010,781.66. This represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 9,164 shares of company stock worth $1,872,363. 8.16% of the stock is owned by corporate insiders.

Key Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Zacks raised multiyear and several quarterly targets — FY2026 to $10.57 (from $10.26), FY2027 to $11.42 and FY2028 to $12.54, and boosted multiple quarters (including Q2/Q3/Q4 2026 and several 2027 quarters). These upward revisions imply a stronger medium‑term earnings trajectory that can support a higher valuation. MarketBeat: DGX analyst notes
• Neutral Sentiment: Small/isolated tweaks — Q3 2027 was nudged +$0.01 to $2.90 and Q1 2026 was raised modestly to $2.37; these changes are too minor on their own to move sentiment meaningfully. MarketBeat: DGX analyst notes
• Negative Sentiment: Zacks trimmed its Q1 2027 estimate to $2.54 from $2.59, a near‑term cut that may weigh on sentiment and explain muted or negative intraday moves despite the larger upward revisions elsewhere. MarketBeat: DGX analyst notes

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on DGX shares. Evercore set a $220.00 price target on shares of Quest Diagnostics in a report on Wednesday, February 11th. Citigroup boosted their target price on Quest Diagnostics from $190.00 to $215.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 10th. Truist Financial raised their price target on Quest Diagnostics from $205.00 to $220.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Jefferies Financial Group upped their price objective on Quest Diagnostics from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Finally, Barclays raised their target price on Quest Diagnostics from $210.00 to $225.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Eight equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $210.29.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.